Objectif Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. Rapid and efficient translation of basic scientific advances into reagents, and targeted molecular leads for preclinical and clinical research and development based on scientific rationales and state-of-the-art technologies, optimally requires an interdisciplinary, collaborative, team-oriented approach. EUCAAD represents a virtual research institute in Europe and consists of 9 research participants including 4 SMEs devoted to the discovery and evaluation of new antibodies for therapy of human cancers. The consortium consists of researchers from SMEs and scientific and clinical centres that have gained international acclaim in this area of research, many of who have worked together in previous EU funded applications e.g. ANGIOSTOP, EUCAPS, ESTDAB and ENACT. Within the consortium there is unique expertise regarding target discovery, target validation, antibody production and initiation of clinical trials. As part of its efforts to translate laboratory research into viable cancer therapies the individual partners has accumulated an extensive portfolio of intellectual property providing a competitive edge to this application. The focus of the grant is the development and evaluation of antibodies against new target structures on tumour cells and blood vessels supplying tumours which are responsible for tumour angiogenesis, progression and metastasis. Collectively, the activities of this consortium can improve the cancer treatment standards in Europe and provide economic benefit to European biotechnology and pharmaceutical research by providing novel immunopharmaceuticals. Champ scientifique medical and health sciencesclinical medicineoncology Mots‑clés Antibodies angiogenesis angiomotin cancer clinical trials endothelial cells neovascularization tumour Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH-2007-1.4-1 - Development and production of new generation antibodies Appel à propositions FP7-HEALTH-2007-A Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur KAROLINSKA INSTITUTET Contribution de l’UE € 2 286 109,90 Adresse Nobels Vag 5 17177 Stockholm Suède Voir sur la carte Région Östra Sverige Stockholm Stockholms län Type d’activité Higher or Secondary Education Establishments Contact administratif Maria Von Witting (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (8) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire BIOINVENT INTERNATIONAL AB Suède Contribution de l’UE € 1 068 920,00 Adresse SOELVEGATAN 41 22370 LUND Voir sur la carte Région Södra Sverige Sydsverige Skåne län Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Stefan Ericsson (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée UNIVERSITE D'AIX MARSEILLE France Contribution de l’UE € 532 098,00 Adresse BOULEVARD CHARLES LIVON 58 LE PHARO 13284 Marseille Voir sur la carte Région Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Type d’activité Higher or Secondary Education Establishments Contact administratif Celine Damon (Ms.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée OXURION Participation terminée Belgique Contribution de l’UE Aucune donnée Adresse GASTON GEENSLAAN 1 3001 Leuven Voir sur la carte Région Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Jean Marie Stassen (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée MARTIN-LUTHER-UNIVERSITAT HALLE-WITTENBERG Allemagne Contribution de l’UE € 425 361,00 Adresse UNIVERSITATSPLATZ 10 6108 Halle Voir sur la carte Région Baden-Württemberg Stuttgart Stuttgart, Stadtkreis Type d’activité Higher or Secondary Education Establishments Contact administratif Peter Waehner (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée UNIVERSITA DEGLI STUDI DI TORINO Italie Contribution de l’UE € 637 504,00 Adresse VIA GIUSEPPE VERDI 8 10124 Torino Voir sur la carte Région Nord-Ovest Piemonte Torino Type d’activité Higher or Secondary Education Establishments Contact administratif Eugenio Rinaldi (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée PHILOCHEM AG Suisse Contribution de l’UE € 309 206,80 Adresse LIBERNSTRASSE 3 8112 Otelfingen Voir sur la carte Région Schweiz/Suisse/Svizzera Zürich Zürich Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Eveline Trachsel (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée PROTAGEN AG Allemagne Contribution de l’UE € 456 640,70 Adresse Otto-Hahn-Strasse 15 44227 DORTMUND Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Sven Rüger (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA Italie Contribution de l’UE € 274 021,60 Adresse Via dei Vestini 31 66013 Chieti Voir sur la carte Région Sud Abruzzo Chieti Type d’activité Higher or Secondary Education Establishments Contact administratif Luciana Gallo (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée